Evidence map›Paper›PMID 27256135›Full record

ArticleThe Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics2016

Contrasting Medical and Legal Standards of Evidence: A Precision Medicine Case Study.

Gary E Marchant, Kathryn Scheckel, Doug Campos-Outcalt

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. From Genetics to Genomics: Facing the Liability Implications in Clinical Care.The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics · 2020
    Article
  3. Navigating the research-clinical interface in genomic medicine: analysis from the CSER Consortium.Genetics in medicine : official journal of the American College of Medical Genetics · 2018
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Gary E MarchantGary Marchant, Ph.D., J.D., M.P.P., is the Regents' Professor and Lincoln Professor of Emerging Technologies, Law & Ethics at the Sandra Day O'Connor College of Law at Arizona State University. He is also the Faculty Director of the Center for Law, Science & Innovation at ASU. He has a Ph.D. (Zoology) from the University of British Columbia, Vancouver, B.C., Canada (1986), a J.D. from Harvard Law School, Cambridge, MA (1990) and a M.P.P. from the Kennedy School of Government, Cambridge, MA (1990). Kathryn Scheckel is the Assistant Director, Special Projects in the Office of University Affairs at Arizona State University. She is a Masters student in Public Policy at ASU, Tempe, AZ (anticipated 2016). She holds a B.S. in Molecular Biosciences & Biotechnology and a B.A. in Piano from ASU, Tempe, AZ (2012). Doug Campos-Outcalt, M.D., M.P.A., is a Medical Director of Mercy Care Plan, Phoenix Arizona. He has an M.D. from the University of Arizona (1979) and an M.P.A. from Arizona State University (1985).
Kathryn ScheckelGary Marchant, Ph.D., J.D., M.P.P., is the Regents' Professor and Lincoln Professor of Emerging Technologies, Law & Ethics at the Sandra Day O'Connor College of Law at Arizona State University. He is also the Faculty Director of the Center for Law, Science & Innovation at ASU. He has a Ph.D. (Zoology) from the University of British Columbia, Vancouver, B.C., Canada (1986), a J.D. from Harvard Law School, Cambridge, MA (1990) and a M.P.P. from the Kennedy School of Government, Cambridge, MA (1990). Kathryn Scheckel is the Assistant Director, Special Projects in the Office of University Affairs at Arizona State University. She is a Masters student in Public Policy at ASU, Tempe, AZ (anticipated 2016). She holds a B.S. in Molecular Biosciences & Biotechnology and a B.A. in Piano from ASU, Tempe, AZ (2012). Doug Campos-Outcalt, M.D., M.P.A., is a Medical Director of Mercy Care Plan, Phoenix Arizona. He has an M.D. from the University of Arizona (1979) and an M.P.A. from Arizona State University (1985).
Doug Campos-OutcaltGary Marchant, Ph.D., J.D., M.P.P., is the Regents' Professor and Lincoln Professor of Emerging Technologies, Law & Ethics at the Sandra Day O'Connor College of Law at Arizona State University. He is also the Faculty Director of the Center for Law, Science & Innovation at ASU. He has a Ph.D. (Zoology) from the University of British Columbia, Vancouver, B.C., Canada (1986), a J.D. from Harvard Law School, Cambridge, MA (1990) and a M.P.P. from the Kennedy School of Government, Cambridge, MA (1990). Kathryn Scheckel is the Assistant Director, Special Projects in the Office of University Affairs at Arizona State University. She is a Masters student in Public Policy at ASU, Tempe, AZ (anticipated 2016). She holds a B.S. in Molecular Biosciences & Biotechnology and a B.A. in Piano from ASU, Tempe, AZ (2012). Doug Campos-Outcalt, M.D., M.P.A., is a Medical Director of Mercy Care Plan, Phoenix Arizona. He has an M.D. from the University of Arizona (1979) and an M.P.A. from Arizona State University (1985).
College of Law · LV

Funding

Liability in the delivery of personalized medicine: driver, impediment, or both?R01HG006145 · NHGRI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI MARCHANT, GARY E. · 2012 to 2014
$865k
NHGRI NIH HHS R01 HG006145
6 · The paper itself

Abstract

As the health care system transitions to a precision medicine approach that tailors clinical care to the genetic profile of the individual patient, there is a potential tension between the clinical uptake of new technologies by providers and the legal system's expectation of the standard of care in applying such technologies. We examine this tension by comparing the type of evidence that physicians and courts are likely to rely on in determining a duty to recommend pharmacogenetic testing of patients prescribed the oral anti-coagulant drug warfarin. There is a large body of inconsistent evidence and factors for and against such testing, but physicians and courts are likely to weigh this evidence differently. The potential implications for medical malpractice risk are evaluated and discussed.

Indexed as

Liability, LegalMalpracticePrecision MedicineAnticoagulantsDelivery of Health CareHumansPhysiciansWarfarinAnticoagulantsWarfarin

Identifiers

PMID27256135
PMCPMC5137582
OpenAlexW2338893644

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.